ALLR

ALLR

Allarity Therapeutics Inc

Net 54.19%top 1%Rev โ€”top 1%Net income grew 100% of yearsRevenue grew 100% of years1Y
Hold

Allarity Therapeutics develops precision medicine for cancer, focusing on novel anti-cancer drugs and companion diagnostics. Its lead candidate is Stenoparib, a dual PARP inhibitor, currently in trials for advanced ovarian cancer, supported by its Drug Response Predictor technology.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$1,458today

Score Overview

1 Year
Scoreโ€”
Net Growth54.19%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth57.85%
Net Trend75%
Net Income Consistency
Rev Growthโ€”
Rev Trend25%
Revenue Consistency

See the full market ranking โ†’

Allarity Therapeutics Inc fundamental performance

Across Allarity Therapeutics Inc's full reported history, from 2021 to 2025, revenue grew from $ 0.00 to $ 320K and net income went from -$ 26M to -$ 11M. Revenue increased in 25% of the years measured; net income in 75%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.40โ€”
1 Year2025-08-12
$ 0.9645.85%
All Time2021-12-21
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 320K-$ 11M$ 14M
2024$ 0.00-$ 24M$ 19M
2023$ 0.00-$ 11M$ 166K
2022$ 0.00-$ 16M$ 2M
IPO2021$ 0.00-$ 26M$ 19M

Explore beyond ALLR

You're looking at Allarity Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies